What Lercanil 10 Treats

Lercanil 10 is a medication primarily used for the management of essential hypertension, commonly known as high blood pressure. High blood pressure occurs when the force of the blood against the artery walls is consistently too high, which can place undue stress on the heart and vascular system over time.

The active ingredient, lercanidipine, belongs to a class of medications called dihydropyridine calcium channel blockers. It works by inhibiting the entry of calcium ions into the smooth muscle cells of the blood vessels. This action causes the blood vessels to relax and widen, a process known as vasodilation, which allows blood to flow more easily and effectively reduces overall blood pressure.

Main Benefits

• Effective Pressure Control: Lercanil 10 helps lower elevated blood pressure toward a target range, which is a key factor in maintaining cardiovascular health.
• Gradual Onset of Action: This medication is characterized by a gradual onset of action, which helps in managing blood pressure levels steadily throughout the day.
• Vascular Selectivity: Lercanidipine is known for its high selectivity for the smooth muscles in the blood vessels compared to the muscle tissues of the heart. This means it focuses on dilating the arteries without significantly affecting the heart's pumping force or heart rate.
• Long-term Management: By maintaining blood pressure within a healthier range, the medication assists in reducing the long-term strain on the cardiovascular system.

Eligibility Map: Who Can and Cannot Use Lercanil 10

The eligibility profile for Lercanil 10 (Lercanidipine) is strictly defined by regulatory documents, allowing its use only in adults for the management of essential hypertension. Use in children and adolescents (under 18) is not recommended, as safety and efficacy have not been established.

Category	Official Regulatory Status
Absolute Contraindications	Use is prohibited in patients with Hypersensitivity to Lercanidipine or any dihydropyridine, severe hepatic impairment, or severe renal impairment (including dialysis).
Cardiovascular Restrictions	Contraindicated in cases of untreated congestive cardiac failure, unstable angina pectoris, recent myocardial infarction (within 1 month), and left ventricular outflow tract obstruction.
Reproductive Status	Lercanil 10 is contraindicated during pregnancy and lactation. Women of child-bearing potential must use effective contraception.
Conditional Use	Special care is required when treatment is initiated in elderly patients, and in those with mild to moderate hepatic or renal impairment or certain cardiac conditions like sick sinus syndrome (without a pacemaker).

The regulatory profile clearly establishes absolute non-eligibility based on the severity of organ dysfunction and cardiovascular instability.

Interactions with other medicines and products

The official interaction profile for Lercanil 10 establishes mandatory constraints based on pharmacokinetic and pharmacodynamic risks documented in regulatory sources.

Formal Contraindications and Substance Restrictions

Co-administration is formally prohibited with Ciclosporin due to a documented increase in the plasma concentrations of both medicines. The use of Lercanil 10 with strong inhibitors of the CYP3A4 enzyme (such as Ketoconazole or Itraconazole) is also contraindicated, as these agents cause a significant increase in Lercanidipine exposure.

The consumption of Grapefruit or Grapefruit Juice must be avoided, as this is documented to inhibit metabolism and increase systemic availability, leading to a potentiated hypotensive effect. Consumption of alcohol is similarly restricted due to the potentiation of the drug’s vasodilating effects.

Metabolic and Exposure-Modifying Interactions

Agents classified as CYP3A4 inducers (e.g., Phenytoin, Carbamazepine, Rifampicin) may reduce the effectiveness of Lercanil 10 by decreasing its plasma concentration.

The profile notes interactions that modify the exposure of co-administered medicines:

• Digoxin co-administration is associated with a documented increase in Digoxin's maximum plasma concentration ( C max).
• Simvastatin exposure is increased upon co-administration; regulatory guidance advises separating the administration (Lercanil 10 in the morning, Simvastatin in the evening) to mitigate this effect.

Population-Specific Constraints

Severe Hepatic and Severe Renal Impairment ( GFR < 30 mL/min) are documented as contraindications, as these conditions are associated with increased systemic exposure and enhanced drug effects.

How Lercanil 10 Works

Targeting Peripheral Calcium Channels

---

Lercanil 10 functions as a selective antagonist of L-type voltage-gated calcium channels located primarily on the smooth muscle cells of peripheral arteries. By binding to these channels, the drug prevents the influx of calcium ions ( Ca^2+) into the cell. As calcium entry is the necessary signal to initiate muscle contraction, this blockade directly results in the relaxation and widening (vasodilation) of the blood vessels.

Systemic Physiological Modulation

---

The subsequent relaxation of the resistance arteries reduces the overall Total Peripheral Resistance (TPR) within the circulatory system. This effect modulates the systemic pressure against which the heart pumps blood, leading directly to a sustained reduction in arterial blood pressure. Furthermore, the drug’s high lipophilicity causes it to be retained within the lipid membrane of the vessel walls, supporting a continuous channel blockade and maintaining the modulation of vascular tone over an extended period.

Lercanil 10 is an oral medication intended for long-term therapeutic use. The approved route of administration is strictly oral, delivered as a film-coated tablet. The medicine is taken once daily at a consistent time each day.

Administration and Dosage Regimen

The standard starting dose for adults is 10 mg, which often serves as the typical maintenance dose. The maximum daily intake is capped at 20 mg. When a dose adjustment is necessary, it is implemented gradually, typically requiring a period of approximately two weeks following the initial treatment before increasing the dose. If a daily dose is missed, the recommendation is to skip the forgotten dose and resume the regimen with the next scheduled tablet; a double dose must not be taken.

Administration Contexts

Proper administration requires the tablet to be swallowed whole with water. Crucially, the medicine must be taken at least 15 minutes before a meal, preferably prior to breakfast, as consuming it with food can significantly affect its systemic absorption. Specific use restrictions include the instruction to avoid taking Lercanil 10 with grapefruit or grapefruit juice, and to avoid alcohol consumption during the course of treatment.

High-level usage rules exist for specific patient populations. For older adults and those with mild to moderate hepatic or renal impairment, special caution is necessary when initiating treatment. The use of the medication is not recommended for patients under 18 years of age due to insufficient data.

Research Evidence / Overview of Studies for Lercanil 10

---

Evidence for the Management of Essential Hypertension

Research has focused extensively on exploring Lercanil 10 in the context of high blood pressure (essential hypertension). The primary research approach has involved Randomized Controlled Trials (RCTs), where patient groups receiving Lercanidipine were compared against groups receiving either an inactive substance (placebo) or other established blood pressure medications. These core studies measured resting Systolic and Diastolic Blood Pressure (SBP/DBP) over short- to intermediate-term follow-up periods to measure changes.

The findings from these controlled studies, often summarized in systematic reviews and meta-analyses that pool data from multiple trials, describe patterns related to blood pressure metrics. Research explored Lercanidipine by comparing it directly against other Calcium Channel Blockers (CCBs), with studies reporting similar patterns in blood pressure measurements across the comparator groups.

The primary outcomes measured in the bulk of this research are surrogate markers (like SBP/DBP measurements), rather than the long-term events like heart attack or stroke. The existing evidence base provides limited insight into how these short-term measurements relate to major event outcomes over many years.

---

Studies in Specific Patient Populations

Dedicated research has been conducted to explore the use of the agent in specific patient groups who often have unique physiological needs.

Research in Older Adult Populations

The study populations in some trials and observational settings specifically included older adults with essential hypertension. These studies examined the patterns of measured outcomes in this population. Findings describe patterns observed in these groups regarding blood pressure measurements, providing context but not individual predictions for all elderly patients.

Studies Including Patients with Renal Impairment

Research has also been applied in studies examining patients with essential hypertension who have co-existing mild renal impairment. In these cohorts, studies monitored specific organ-specific measures such as microalbuminuria (a marker of kidney functional strain). These studies describe patterns observed so far regarding outcomes related to physiological strain in patients facing this specific dual condition.

---

Long-Term Follow-up and Hard Outcomes

Most pivotal registration trials were focused on achieving specific blood pressure targets over a short-term period. However, some research does look further ahead. Observational studies and certain comparative trials have provided data that tracks patients over longer-term periods, sometimes up to several years. This extended data collection explores cardiovascular outcomes by monitoring the occurrence of Major Adverse Cardiovascular Events (MACE), such as heart attack or stroke, in the observed populations. Research examined the rate at which these events were observed in patients taking the agent compared to those taking other treatments.

---

The Landscape of Clinical Evidence and Remaining Uncertainties

The evidence base is largely built on Randomized Controlled Trials (RCTs) and meta-analyses. This research provides data related to observed changes in blood pressure surrogate markers.

However, certainty remains low in certain areas. One notable limitation is the current state of long-term outcomes data. Dedicated, large-scale RCTs focused solely on long-term cardiovascular morbidity and mortality specifically comparing the agent to placebo or non-CCB classes are less frequent than shorter-term trials. Therefore, long-term effects are not fully established based on the highest level of randomized evidence.

Furthermore, evidence is limited and often heterogeneous for patients with severe, resistant hypertension or those with advanced Chronic Kidney Disease. Data for these more complex groups are still emerging, and subgroup findings are uncertain.

Key Studies & References

1. Public Assessment Report Scientific discussion Lercanidipinhydrochlorid ”Actavis” DK/H/1490/001-002/DC

Common questions about Lercanil 10 (FAQ)

Q: Is Lercanil 10 a generic or brand name medicine?

A: Lercanil 10 is the brand name for the active ingredient, which is Lercanidipine hydrochloride. The medicine may also be available under the generic name (Lercanidipine) or other authorized brand names.

Q: Is Lercanil 10 the same as other blood pressure medicines?

A: The medicine is classified as a Calcium Channel Blocker (CCB), which is one type of medicine used for high blood pressure. Official research has examined Lercanil 10 in comparison to other calcium channel blockers (CCBs) and different types of antihypertensive agents.

Q: How does Lercanil 10 compare to the main class of blood pressure drugs?

A: Studies have examined Lercanil 10 by comparing it to agents from different therapeutic classes. These comparisons describe that the reduction in blood pressure was observed across the compared groups, suggesting a similar pattern of effect.

Q: How quickly does Lercanil 10 start to work?

A: According to official product information, the peak concentration of the medicine in the blood is typically reached about 1.5 to 3 hours after a dose. However, a sustained reduction in blood pressure may take approximately two weeks of consistent daily use to become apparent.

Q: How long does the effect of one Lercanil 10 tablet last?

A: The medicine is designed to have a long-acting profile. Its therapeutic activity is intended to last for 24 hours, which is consistent with its official once-daily administration schedule.

Q: Is Lercanil 10 safe to take long term?

A: This medicine is often prescribed for the long-term management of high blood pressure. Clinical studies have monitored patients for periods up to several years to track effects and cardiovascular outcomes over time.

Q: What happens if I stop taking Lercanil 10 suddenly?

A: Discontinuation of any medicine used for blood pressure control may result in the blood pressure rising again. This increase in blood pressure may raise the associated cardiovascular risk.

Q: Is it okay to drink alcohol in moderation while on Lercanil 10?

A: Official regulatory documents recommend avoiding alcohol while taking this medicine. Alcohol consumption may enhance the effects of vasodilating medicines, potentially leading to effects like dizziness or abnormally low blood pressure.

Q: Can Lercanil 10 affect kidney function?

A: Regulatory documents state the medicine is contraindicated in severe renal impairment. Studies involving patients with mild kidney issues have described observations of a neutral pattern of effect on specific kidney function measures.

Q: Does Lercanil 10 affect blood sugar levels?

A: Official documentation indicates that this medicine does not appear to adversely influence blood sugar levels in patients.

Q: Does Lercanil 10 affect cholesterol levels?

A: Official documentation indicates that this medicine does not appear to adversely influence serum lipid levels, which include cholesterol.

Q: Does Lercanil 10 cause drowsiness or affect driving?

A: Possible side effects include dizziness, fatigue, or asthenia (weakness). Official patient information notes that caution is necessary, as the medicine may affect the ability to drive or operate machinery.

Q: Is it common to have headaches when first starting Lercanil 10?

A: Headache is listed in regulatory documents as a Common side effect, affecting up to 1 in 10 people. These effects are described in regulatory documents as often being mild and temporary when treatment is first initiated.

Q: Can people with certain allergies not take Lercanil 10?

A: Official regulatory information specifies that the medicine must not be used if a patient has a known hypersensitivity (allergy) to the active substance, Lercanidipine, or to any other medicine belonging to the dihydropyridine group.

Q: Is Lercanil 10 approved for use in children?

A: Use of this medicine is not recommended for children and adolescents under 18 years of age. This restriction is because the safety and efficacy data for this age group have not been established by regulatory bodies.

Q: Is Lercanil 10 used for conditions other than high blood pressure?

A: The official regulatory indication for this medicine is the treatment of essential hypertension (high blood pressure) in adults.

Q: Is Lercanil 10 habit-forming or addictive?

A: Based on official patient information, there is no regulatory evidence indicating that this medicine is considered habit-forming or addictive.

Q: Does Lercanil 10 have any known drug interactions with supplements?

A: Regulatory sources have limited specific information documented regarding the interaction between this medicine and various herbal remedies or nutritional supplements.

Q: What kind of studies support the use of Lercanil 10?

A: The evidence base is largely built on Randomized Controlled Trials (RCTs) and meta-analyses that pool data from multiple trials. These studies have primarily measured changes in Systolic and Diastolic Blood Pressure (SBP/DBP).

Q: What research is available on Lercanil 10 and heart health?

A: Research has primarily focused on the medicine's effect on short-term blood pressure measurements. Longer-term observational studies have also tracked the occurrence of Major Adverse Cardiovascular Events (MACE), such as heart attack or stroke, in the studied patient populations.

How to Store and Dispose of Lercanil 10

The storage and disposal of Lercanil 10 (lercanidipine hydrochloride 10 mg tablets) must comply strictly with official regulatory guidelines to maintain product integrity and environmental safety.

Official Storage Conditions

Requirement	Constraint
Temperature	Do not store above 25°C.
Protection	Must be stored in the original package to protect from moisture.
Container	Keep the container tightly closed (where applicable).
Child Safety	Keep out of the sight and reach of children.

Official Disposal Instructions

To discard unused or expired Lercanil 10, do not throw away any medicines via wastewater or household waste.

Disposal of unused medicinal product or waste material must be done in accordance with local requirements. Patients are directed to consult their pharmacist regarding the proper disposal procedure for the unused medicine.